chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually have chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable & treatable disease.

Introduction

  • Chronic Obstructive Pulmonary Disease (COPD) should be suspected in any patient who has chronic cough, sputum production or dyspnea w/ or w/o history of risk factors for the disease

Definition

  • A preventable & treatable disease w/ overall severity contributed by exacerbations & comorbidities
  • The persistent airflow limitation is usually progressive & associated w/ an enhanced chronic inflammatory response in the airways & the lung to noxious particles or gases
  • The chronic airflow limitation is caused by a mixture of small airways disease & parenchymal destruction

Signs and Symptoms

A diagnosis of COPD should be considered in patients over 40 yr of age who have a suggestive medical history (ie presence of risk factors) & who present w/ any of the following:

  • Chronic cough (present intermittently or daily) & sputum production of at least 3 mth in each of 2 consecutive yr
    • Does not reflect the major impact of airflow limitation on the morbidity & mortality in patients w/ COPD
    • Cough may be unproductive
  • Exertional breathlessness, wheezing, pursed-lip breathing, dyspnea w/ or w/o wheezing
  • Rhonchi, prolonged expiratory phase of respiration, chest hyperinflation, use of accessory muscles for respiration, decreased breath sounds
  • Signs of cor pulmonale: Neck vein distention, increased pulmonic component of 2nd heart sound, lower extremity edema, hepatomegaly
  • The absence of wheezing or chest tightness does not rule out a diagnosis of COPD

Risk Factors

Host Factors

  • Hereditary deficiency of alpha-1 antitrypsin
  • Airway hyper-responsiveness
    • Includes asthma
    • May also develop after exposure to tobacco smoke or other environmental insults
  • Lung growth & development
    • Individuals may have reduced maximal attained lung function due to processes during gestation & childhood
  • Infections
    • Reduced lung function can be associated w/ a history of severe childhood resp infections
    • Previous tuberculosis

Exposures

  • Tobacco smoke
    • Most commonly encountered risk factor
    • Includes history of tobacco use or prolonged exposure to second-hand smoke
    • Smoking during pregnancy can put the fetus at risk
  • Occupational dusts & chemicals
  • Air pollution
  • Smoke from home cooking & heating fuels
  • Socioeconomic status
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Radha Chitale, 2 years ago
Traffic and smog pollutants can alter airborne allergens to make them more potent, new research shows.
7 months ago
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
6 months ago
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Naomi Rodrig, 2 years ago
The BRAF inhibitors vemurafenib and dabrafenib, currently approved for use in advanced melanoma, are also effective in a subset of lung adenocarcinoma patients with BRAF mutations, according to a retrospective European trial presented at the European Lung Cancer Conference (ELCC) held in Geneva, Switzerland.